Last updated on March 2018

Study on Androgen Receptor and Triple Negative Breast Cancer

Brief description of study

This is a multicenter uncontrolled, open-label, prospective, non-comparative randomized, phase II study. Patients will be randomized between darolutamide in Arm n1 (two-stage Simon's design) and capecitabine in Arm n2 with two patients randomized in Arm n1 for one patient randomized in Arm n2.

The trial population is composed of women over 18 years old with triple-negative and androgen receptor positive, locally recurrent (unresectable) or metastatic breast cancer.

Clinical Study Identifier: NCT03383679

Find a site near you

Start Over